A5002055787- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Kruppel-like factors research
- Histone Deacetylase Inhibitors Research
- Retinoids in leukemia and cellular processes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Lupus Erythematosus Research
- Blood disorders and treatments
- Cancer survivorship and care
- Acute Lymphoblastic Leukemia research
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Cytokine Signaling Pathways and Interactions
- Hemoglobinopathies and Related Disorders
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Systemic Sclerosis and Related Diseases
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
Klinikum Wels-Grieskirchen
2011-2020
Barmherzige Schwestern vom heiligen Kreuz
2004-2020
Ordensklinikum Linz Barmherzige Schwestern
2019
Innsbruck Medical University
2019
Johannes Kepler University of Linz
2019
Medical University of Graz
2019
Landeskrankenhaus Feldkirch
2019
Comprehensive Cancer Center Vienna
2019
Medical University of Vienna
2019
Paracelsus Medical University
2019
Background Treatment of follicular lymphoma with rituximab is currently recommended at a dose 375 mg/m2. We aimed to provide rationale for optimal dosing and scheduling this anti-CD20 antibody based on pharmacokinetics.Design Methods Clinical efficacy immunochemotherapy rituximab, fludarabine mitoxantrone followed by 2-monthly maintenance was evaluated in 29 patients previously untreated prospective phase II trial (AGMT-NHL9). Pharmacokinetic analysis assessed 17 patients.Results Induction...
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, the drug can only be used off-label these patients. We previously reported 155 AML patients treated within Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). herein update this report a population almost twice as large (n = 302). This cohort included 172 BM blasts; 93 would have been excluded from pivotal AZA-001 trial (which led to European...
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, 27/1715 (1.6%) cases referred investigation eosinophilia. Of 27 mutated cases, working diagnosis hypereosinophilic syndrome (HES; n = 7) or myeloid neoplasm with (n 20) had been made prior to detection N642H. Myeloid panel analysis median 2 additional genes (range 0–4) 4...
We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular grade 3b (n=21) first complete remission. Patients were randomized to (n=338) observation (n=345). At a median follow-up of 45 months, the event-free survival rate (the primary endpoint) at 3 years was 80.1% for versus 76.5% observation. This difference not statistically significant intent-to-treat population (likelihood ratio P=0.0670). The hazard by treatment arm 0.79 (95%...
Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition CXCR4 CXCR7 signaling reduces protective activity bone marrow lymph node microenvironment. CXCL12 mobilizes cells into circulation prevents their homing niches. In this phase I/II study, 28 patients with relapsed/refractory were treated olaptesed in combination bendamustine...
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival as compared best supportive care (62% vs. 41%, p=0.067) longer OS first-line hydroxyurea...
The Austrian Azacitidine Registry is a multi-center database (ClinicalTrials.gov: NCT01595295). nature and intent of the registry was to gain comprehensive view use, safety efficacy drug in broad range AML-patients treated real-life scenarios.The sole inclusion criteria were diagnosis WHO-AML treatment with at least one dose azacitidine. No formal exclusion existed. A total 155 who mostly unfit/ineligible for intensive chemotherapy, or had progressed despite conventional treatment, included....
The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydrogenase and splenomegaly. In this study, we evaluated relative frequency these in a group 170 pre-PMF patients compared them to 225 ET cases. More than 91% cases showed or more features required diagnosis, by contrast with only 48% patients. According data cumulative...
Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of Standards in Haematology (BCSH) criteria that are predominantly based on exclusion and not necessarily bone marrow (BM) morphology, or World Health Organization (WHO) require BM examination as essential criterion. We studied morphological clinical features patients according to BCSH (n=238) WHO guidelines (n=232). The BCSH-defined ET cohort was re-evaluated applying classification. At presentation, group...
We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated front-line azacitidine versus conventional care regimens within phase 3 clinical trial (AZA-AML-001; NCT01074047; registered: February 2010). As results obtained trials are facing increased pressure to be confirmed by real-world data, we aimed test whether data the...
The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance advanced pancreatic ductal adenocarcinoma (PDAC) not yet studied. In the present study we investigated AST/ALT as a possible predictor of treatment response and disease outcome patients with PDAC treated first-line gemcitabine/nab-paclitaxel.A post hoc analysis prospective, multicenter, noninterventional was...
Fifty‐one polycythemia vera (PV) patients were enrolled in the phase I/II clinical study PEGINVERA to receive a new formulation of pegylated interferon alpha (peg‐proline‐IFNα‐2b, AOP2014/P1101). Peg‐proline‐IFNα‐2b treatment led high response rates on both hematologic and molecular levels. Hematologic responses achieved for 46 18 (90 35% whole cohort), respectively. Although (IFNα) is known be an effective antineoplastic therapy long time, it currently not well understood which genetic...
The MDS-IWG and NCCN currently endorse both FAB WHO classifications of MDS AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised treated as either or AML. In addition, an artificial distinction between AML20-30 AML30+ was made by regulatory agencies initially restricting approval azacitidine AML20-30. Thus, uncertainty prevails regarding the diagnosis, prognosis optimal treatment timing strategy for Here, we aim provide clarification...
Abstract We describe the fusion of TP53BP1 to PDGFRB in a patient with chronic myeloid leukemia-like disorder associated eosinophilia and t(5;15)(q33;q22). encodes 53BP1, p53-binding protein that plays role cellular responses DNA damage. The 53BP1-PDGFRβ is predicted retain kinetochore-binding domain 53BP1 fused transmembrane intracellular tyrosine kinase PDGFRβ. presence was confirmed by two-color fluorescence situ hybridization, reverse transcription-PCR, characterizing genomic...
Acute erythroleukemia (AEL) is a rare disease typically associated with poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong in patients myelodysplastic syndromes (MDS) and AML, but there limited data of their efficacy AEL. We collected 210 AEL treated at 28 international sites. Overall (OS) PFS were estimated using the Kaplan-Meier method log-rank test was used for subgroup comparisons. Survival...
Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and Leukemia Foundation (LRF) developed a score for older AML patients receiving IC non-intensive regimens, whereas E-ALMA study validated response elderly daily practice. Both identified three groups with different risk estimates. This analysis evaluates efficacy of frontline (N = 710) unfit from national...